DIOGENX
DiogenX is a preclinical stage biotech company, specializing in the development of pancreatic beta-cell modulators for the treatment of Type 1 (T1D) and Type 2 Diabetes (T2D). The company, which also has research labs in Nice, France, aims to discover and develop a candidate molecule that regenerates pancreatic insulin-producing cells in patients with diabetes, offering benefits in terms of quality of life and survival. It was discovered in the laboratory of Dr. Patrick Collombat (Inserm, CNRS, Nice University) in France, DiogenX is developing an innovative therapy with the potential to be the first beta-cell regeneration drug for diabetes.
DIOGENX
Industry:
Biotechnology Life Science
Founded:
2019-01-01
Address:
Marseille, Provence-Alpes-Cote D'Azur, France
Country:
France
Website Url:
http://www.diogenx.com
Total Employee:
1+
Status:
Active
Total Funding:
4.5 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics WordPress Google Universal Analytics Font Awesome Apache
Similar Organizations
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
RNAimmune
RNAimmune is a biopharmaceutical company specializing in the discovery and development of mRNA-based therapeutics and vaccines.
Current Advisors List
Current Employees Featured
Founder
Investors List
JDRF T1D Fund
JDRF T1D Fund investment in Seed Round - DiogenX
AdBio partners
AdBio partners investment in Seed Round - DiogenX
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund investment in Seed Round - DiogenX
Official Site Inspections
http://www.diogenx.com
- Host name: cluster029.hosting.ovh.net
- IP address: 51.91.236.255
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "DiogenX"
About us - DioGenX
DiogenX is a biotech company focused on regenerating insulin-producing beta cells for the treatment of diabetes. Founded in 2020, its work is based on the pancreatic beta cell …See details»
DiogenX - Crunchbase Company Profile & Funding
DiogenX is a preclinical stage biotech company, specializing in the development of pancreatic beta-cell modulators for the treatment of Type 1 (T1D) and Type …See details»
DiogenX Raises €27.5M Series A Financing to Advance its First-in …
May 10, 2023 DiogenX previously raised €4.5M ($4.8M) in June 2020. ... The T1D Fund invests in areas strategically aligned with JDRF, the leading global organization funding T1D research, …See details»
DiogenX - LinkedIn
DiogenX is a preclinical stage biotech company committed to a single mission: to discover and develop innovative biologics as new therapeutics options for millions of Diabetic patients around the ...See details»
DiogenX - Overview, News & Similar companies | ZoomInfo.com
DiogenX is a preclinical stage biotech company committed to a single mission: to discover and develop innovative biologics as new therapeutics opti ons for millions of Diabetic patients …See details»
DiogenX - VentureRadar
" DiogenX is a preclinical stage biotech company committed to a single mission: to discover and develop innovative biologics as new therapeutics options for millions of Diabetic patients …See details»
DiogenX Company Profile - Office Locations, Competitors ... - Craft
DiogenX is a company that develops therapeutic solutions intended to serve diabetic patients. The company provides pancreatic beta-cell modulators for the treatment of type 1 and type 2 …See details»
Diogenx Company Profile 2024: Valuation, Funding & Investors
Diogenx General Information Description. Developer of therapeutic services intended to serve diabetic patients. The company provides pancreatic beta-cell modulators for the treatment of …See details»
DiogenX - Products, Competitors, Financials, Employees, …
DiogenX welcomes Eleanor L. Ramos as independent member of its Board of Directors. Sep 9, 2024. DiogenX welcomes Eleanor L. Ramos as independent member of its Board of Directors …See details»
DiogenX - Sunstone
DiogenX is developing a first-in-class recombinant protein that aims to replicate insulin-producing beta cells in the pancreas of type 1 diabetes patients. This novel approach has the potential to …See details»
DiogenX - EU-Startups
DiogenX is a preclinical stage biotech company, specializing in the development of pancreatic beta-cell modulators for the treatment of Type 1 (T1D) and Type 2 Diabetes (T2D). Its aim is …See details»
Our approach - DioGenX
In this context, DiogenX’s approach has a unique off-the shelf profile for symptomatic T1D patients. With the potential to regenerate the patient’s own beta cell and restore its own …See details»
DiogenX - Contacts, Employees, Board Members, Advisors & Alumni
DiogenX has 3 current employee profiles, including Co-Founder Patrick Collombat. DiogenX has 5 board members and advisors, including Johannes Zanzinger . ContactsSee details»
DiogenX (FR), Research Lab Nice (Institut de Biologie Valrose)
Dec 1, 2019 DiogenX is a biotech company focused on regenerating insulin-producing beta cells for the treatment of diabetes. Founded in 2020 based on the research of leading type 1 …See details»
DiogenX - Funding, Financials, Valuation & Investors - Crunchbase
DiogenX is a preclinical stage biotech company specializing in the development of pancreatic beta-cell modulators. Search Crunchbase. Start Free Trial . ... How much funding has this …See details»
DiogenX | The Pharmaletter
The company is developing first-in-class recombinant proteins designed for the treatment of T1D. DiogenX’s lead program DGX-01 modulates the Wnt/β-catenin signalling pathway to …See details»
DiogenX raises €27.5M Series A financing to advance its first-in …
DiogenX previously raised €4.5M ($4.8M) in June 2020. DiogenX’s lead program aims to regenerate pancreatic insulin-producing beta cells using ... the leading global organization …See details»
DiogenX strengthens Executive Committee with Hélène Sicard …
Marseille, France, July 25, 2024 – DiogenX, a biotech company focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of …See details»
DiogenX raises $30M for regenerative diabetes treatment
May 12, 2023 DiogenX announced that it completed a $30 million Series A financing round to support its regenerating insulin-producing beta cells. Marseille, France-based DiogenX aims to …See details»